NPPA issued a notification regarding fixation of the retail price of Relugolix 40 mg + Estradiol Hemihydrate USP eq. to Estradiol 1 mg + Norethindrone Acetate USP 0.5 mg for M/s Macmillon Pharmaceuticals Pvt. Ltd. (Manufacturer) & M/s Zydus Healthcare Ltd. (Marketer)

Apr 14, 2026 | by TeamLease RegTech Legal Research Team

Free Legal updates for the week 00


Industry Specific ComplianceThe National Pharmaceutical Pricing Authority (NPPA) on April 13, 2026, issued a notification regarding fixation of the retail price of Relugolix 40 mg + Estradiol Hemihydrate USP eq. to Estradiol 1 mg + Norethindrone Acetate USP 0.5 mg for M/s Macmillon Pharmaceuticals Pvt. Ltd. (Manufacturer) & M/s Zydus Healthcare Ltd. (Marketer).

The following has been stated: -

•For each tablet containing Relugolix 40 mg + Estradiol Hemihydrate USP eq. to Estradiol 1 mg + Norethindrone Acetate USP 0.5 mg for M/s Macmillon Pharmaceuticals Pvt. Ltd. (Manufacturer) & M/s Zydus Healthcare Ltd. (Marketer) the retail price is 116 (Rs).

The detailed notification is given in the document below.

[Notification No.: 19(5112)/2026/DP/NPPA/Div.III/13601/2026]


Bookmark

Related Updates



Alternate Text

Get updates on the go on RegUpdate Mobile App.

NEW  ·  AI ASSISTANT